Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Theracryf Plc

Healthcare GB TCF

0.225GBX
0.00(0%)

Last update at 2026-06-05T11:04:00Z

Day Range

0.220.22
LowHigh

52 Week Range

0.170.30
LowHigh

Fundamentals

  • Previous Close 0.23
  • Market Cap4.19M
  • Volume1002405
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2.20700M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM -2.23300M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Income before tax -2.08500M -3.56600M -5.00600M -3.16900M -3.21300M
Minority interest - - - - -
Net income -1.94100M -3.13700M -4.04300M -2.73000M -2.67400M
Selling general administrative 0.90M 1.16M 0.77M 0.56M 0.64M
Selling and marketing expenses - 0.01M 0.01M 0.01M 0.02M
Gross profit -2.11200M 0.39M 0.43M -0.01600M -3.19500M
Reconciled depreciation 0.07M 0.01M 0.01M 0.02M 0.02M
Ebit -2.12400M -3.56000M -5.00600M -3.16900M -3.21300M
Ebitda -2.05500M -3.54900M -4.99300M -3.15300M -3.19500M
Depreciation and amortization 0.07M 0.01M 0.01M 0.02M 0.02M
Non operating income net other - - - - -
Operating income -2.12400M -3.56000M -5.07000M -3.19100M -3.20400M
Other operating expenses 2.12M 3.96M 5.51M 3.19M 3.40M
Interest expense - - - - -
Tax provision -0.14400M -0.42900M -0.96300M -0.43900M -0.53900M
Interest income 0.00500M 0.00000M 0.10M 0.02M 0.00000M
Net interest income 0.00500M 0.00000M 0.10M 0.02M 0.00000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.14M -0.42900M -0.96300M -0.43900M -0.53900M
Total revenue 0.00000M 0.40M 0.44M 0.00000M 0.19M
Total operating expenses 0.01M 3.94M 5.50M 3.17M 3.38M
Cost of revenue 2.11M 0.01M 0.01M 0.02M 3.39M
Total other income expense net 0.04M -0.00600M 0.10M 0.02M -0.00900M
Discontinued operations - - - - -
Net income from continuing ops -1.94100M -3.13700M -4.04300M -2.73000M -2.67400M
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Total assets 7.63M 3.06M 6.17M 9.64M 12.42M
Intangible assets 2.46M 0.03M 0.04M 0.05M 0.07M
Earning assets - - - - -
Other current assets 0.65M 0.53M 0.11M 0.07M 0.10M
Total liab 1.66M 0.72M 0.83M 0.41M 0.61M
Total stockholder equity 5.97M 2.34M 5.34M 9.23M 11.81M
Deferred long term liab - - - - -
Other current liab 1.53M 0.36M 0.40M 0.32M 0.17M
Common stock 5.32M 0.69M 0.69M 0.69M 0.69M
Capital stock 5.32M 0.69M 0.69M 0.69M 0.69M
Retained earnings -30.43200M -28.91800M -23.72500M -19.82000M -17.10500M
Other liab - - - - -
Good will - - - - -
Other assets - 0.00000M - 0.00000M 0.00000M
Cash 2.11M 2.00M 5.00M 4.51M 5.59M
Cash and equivalents - - - - -
Total current liabilities 1.66M 0.72M 0.83M 0.41M 0.61M
Current deferred revenue - - - - -
Net debt -2.10900M -2.00400M -5.00000M -4.51000M -5.59300M
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity 28.70M 27.87M 27.87M 27.87M 27.87M
Property plant equipment - - - - -
Total current assets 5.17M 3.03M 6.13M 9.58M 12.35M
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments 2.00M - - 4.52M 6.00M
Net receivables 0.40M 0.50M 1.02M 0.48M 0.65M
Long term debt - - - - -
Inventory - -0.00100M - - -
Accounts payable 0.11M 0.33M 0.40M 0.07M 0.41M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 2.38M 2.70M 0.51M 0.49M 0.36M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.00100M - -0.00000M -0.00000M
Deferred long term asset charges - - - - -
Non current assets total 2.46M 0.04M 0.05M 0.06M 0.07M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Investments -2.07500M 0.00000M 4.62M 1.50M -6.00500M
Change to liabilities - - - - -
Total cashflows from investing activities -2.07500M - 4.52M 1.48M -6.00500M
Net borrowings - - - - -
Total cash from financing activities 4.55M - - - 10.39M
Change to operating activities - - - - -
Net income -2.08500M -3.56600M -4.04300M -2.73000M -2.67400M
Change in cash 0.10M -2.99600M 0.49M -1.08300M 1.46M
Begin period cash flow 2.00M 5.00M 4.51M 5.59M 4.13M
End period cash flow 2.11M 2.00M 5.00M 4.51M 5.59M
Total cash from operating activities -2.36700M -2.99600M -4.02900M -2.56000M -2.92600M
Issuance of capital stock 5.15M 0.00000M - 0.00000M 11.11M
Depreciation 0.07M 0.01M 0.01M 0.02M 0.02M
Other cashflows from investing activities -2.00000M - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 0.08M -0.37900M -0.09100M 0.11M -0.03900M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.60500M - 4.52M 1.48M -0.71700M
Change to netincome - - - - -
Capital expenditures 0.00000M 0.00000M 0.00100M 0.00300M 0.00500M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.49300M -0.49100M 0.33M -0.08600M -0.08500M
Stock based compensation 0.12M 0.14M 0.16M 0.15M -0.11200M
Other non cash items 0.03M 0.91M -0.48800M 0.09M -0.07300M
Free cash flow -2.36700M -2.99600M -4.03000M -2.56300M -2.93100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
TCF
Theracryf Plc		 - -% 0.23 - - 2.79 0.87 2.49 0.32
GNS
Genus PLC		 - -% 2274.00 36.08 26.18 2.53 3.46 2.92 15.38
ONT
Oxford Nanopore Technologies Ltd		 -9.7 6.93% 130.30 - - 4.71 2.50 4.23 -8.8899
OXB
Oxford BioMedica PLC		 30.00 5.00% 630.00 - 208.33 4.05 7.60 4.42 308.96
AVCT
Avacta Group PLC		 1.50 2.14% 71.50 - - 2849.46 1929.84 2525.51 -12.0368

Reports Covered

Stock Research & News

View All

Profile

Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat fatigue and narcolepsy. It also develops SFX-01 for the treatment of brain cancer glioblastoma and neurodevelopmental disorders. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.

Theracryf Plc

Alderley Park, Nether Alderley, United Kingdom, SK10 4TG

Key Executives

Name Title Year Born
Dr. Huw Jones BSc, Ph.D. CEO & Executive Director 1959
Mr. Toni Haenninen CFO & Director 1977
Dr. Helen Kuhlman Ph.D. Chief Operating Officer NA
Dr. Glen Clack FFPM, M.D. Chief Medical Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions